"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 5 | 8 | 13 |
| 2013 | 9 | 4 | 13 |
| 2014 | 5 | 7 | 12 |
| 2015 | 15 | 8 | 23 |
| 2016 | 8 | 14 | 22 |
| 2017 | 11 | 11 | 22 |
| 2018 | 11 | 17 | 28 |
| 2019 | 19 | 19 | 38 |
| 2020 | 6 | 22 | 28 |
| 2021 | 14 | 28 | 42 |
| 2022 | 4 | 35 | 39 |
| 2023 | 2 | 34 | 36 |
| 2024 | 20 | 30 | 50 |
| 2025 | 9 | 26 | 35 |
| 2026 | 7 | 18 | 25 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Pan-tumor spatial transcriptomics reveals conserved properties of tumor organization. Cell Rep Med. 2026 Sep 15; 7(9):103013.
-
Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells. Nat Cancer. 2026 Sep; 7(9):1387-1405.
-
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36? plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clin Cancer Res. 2026 Aug 14; 32(16):3493-3505.
-
Microenvironmental arginine restriction sensitizes pancreatic cancers to polyunsaturated fatty acids by suppression of lipid synthesis. Elife. 2026 Aug 05; 14.
-
Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions. Cancer. 2026 Aug 01; 132(15):e70526.
-
Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Sci Adv. 2026 Jul 24; 12(30):eadz1388.
-
Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment. Clin Cancer Res. 2026 Jul 17; 32(14):2885-2897.
-
Disrupting Treg lineage stability elicits RORgT-mediated plasticity and enhances anti-tumor immunity. Cell Death Dis. 2026 Jul 06; 17(1).
-
Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy. J Transl Med. 2026 06 26; 24(1).
-
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care. Cell Rep Med. 2026 Jun 16; 7(6):102790.